Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. News
  7. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Affimed N : Q1 Revenue Advances

07/01/2021 | 07:55am EDT


© MT Newswires 2021
All news about AFFIMED N.V.
09/08AFFIMED N : Earnings Flash (AFMD) AFFIMED N.V. Posts Q2 Revenue $9.71M, vs. Stre..
MT
09/08AFFIMED N : UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Form ..
PU
09/08AFFIMED N : Q2 Loss Flat, Revenue Rises
MT
09/08Affimed Reports Second Quarter 2021 Financial Results and Highlights Operatio..
GL
09/07AFFIMED N : 2021 Virtual Wells Fargo Healthcare Conference
PU
09/06AFFIMED N : Second Quarter 2021 Financial Results and Corporate Update Conferenc..
PU
08/26AFFIMED N : to Present at Upcoming Investor Conferences
AQ
08/23AFFIMED N : to Report Second Quarter 2021 Financial Results & Corporate Update o..
AQ
08/02AFFIMED N : Announces Publication of Comprehensive Preclinical Data Demonstratin..
AQ
07/30AFFIMED N : Announces Publication of Comprehensive Preclinical Data Demonstratin..
AQ
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Financials
Sales 2021 40,6 M 47,7 M 47,7 M
Net income 2021 -57,4 M -67,5 M -67,5 M
Net Debt 2021 - - -
P/E ratio 2021 -11,1x
Yield 2021 -
Capitalization 641 M 758 M 754 M
Capi. / Sales 2021 15,8x
Capi. / Sales 2022 10,5x
Nbr of Employees 153
Free-Float 97,2%
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | AFMD | NL0010872420 | MarketScreener
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,36 €
Average target price 12,48 €
Spread / Average Target 133%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Executive Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.8.76%758
GILEAD SCIENCES, INC.23.17%89 973
BIONTECH SE335.78%85 800
REGENERON PHARMACEUTICALS34.96%67 787
WUXI APPTEC CO., LTD.28.41%64 886
VERTEX PHARMACEUTICALS-20.09%48 996